Bristol Myers Squibb disclosed Phase 3 results from the SUCCESSOR-2 study showing its cereblon E3 ligase modulator mezigdomide (MeziKd) nearly doubles median progression-free survival in relapsed or refractory multiple myeloma. In data presented at ASCO, adding mezigdomide reduced the risk of disease progression or death by 52% versus carfilzomib plus dexamethasone alone. BMS reported median PFS of 18 months with the mezigdomide regimen versus 8.3 months for the comparator, alongside higher response rates including deeper complete responses. The company also noted a higher frequency of grade 3/4 treatment-related adverse events in the mezigdomide arm. The readout strengthens BMS’ strategy to position a next generation of CELMoDs as successors to its longstanding myeloma franchise, setting up potential further regulatory dialogue and head-to-head pressure as cell therapies and bispecific antibodies expand in earlier lines.